Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small cell lung cancer (NSCLC) (Abstract LBA3).
Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).
Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
